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Abstract
Osteoporosis is a major complication of chronic cholestatic liver disease (CCLD). We evaluated the efficacy of using disodium 
pamidronate (1.0 mg/kg body weight) for the prevention (Pr) or treatment (Tr) of cholestasis-induced osteoporosis in male Wistar 
rats: sham-operated (Sham = 12); bile duct-ligated (Bi = 15); bile duct-ligated animals previously treated with pamidronate before 
and 1 month after surgery (Pr = 9); bile duct-ligated animals treated with pamidronate 1 month after surgery (Tr = 9). Rats were 
sacrificed 8 weeks after surgery. Immunohistochemical expression of IGF-I and GH receptor was determined in the proximal 
growth plate cartilage of the left tibia. Histomorphometric analysis was performed in the right tibia and the right femur was used 
for biomechanical analysis. Bone material volume over tissue volume (BV/TV) was significantly affected by CCLD (Sham = 
18.1 ± 3.2 vs Bi = 10.6 ± 2.2%) and pamidronate successfully increased bone volume. However, pamidronate administered in 
a preventive regimen presented no additional benefit on bone volume compared to secondary treatment (BV/TV: Pr = 39.4 ± 
12.0; Tr = 41.2 ± 12.7%). Moreover, the force on the momentum of fracture was significantly reduced in Pr rats (Sham = 116.6 
± 23.0; Bi = 94.6 ± 33.8; Pr = 82.9 ± 22.8; Tr = 92.5 ± 29.5 N; P < 0.05, Sham vs Pr). Thus, CCLD had a significant impact on 
bone histomorphometric parameters and pamidronate was highly effective in increasing bone mass in CCLD; however, preven-
tive therapy with pamidronate has no advantage regarding bone fragility.
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Hepatic osteodystrophy is a generic term used to identify 
bone diseases associated with the complex metabolic distur-
bance linked to liver diseases, especially chronic cholestatic 
liver disease (CCLD) (1). Osteoporosis is the major bone 
complication of CCLD. Multiple factors contribute to bone 
loss in CCLD and all can be easily recognized at the end 
stage of chronic liver disease (malnutrition, hypogonadism, 
vitamin D deficiency, insulin-like growth factor-I (IGF-I) defi-
ciency, and cholestasis) (2). However, decreased production 
of endocrine IGF-I by the liver (3,4), as well as paracrine/
autocrine IGF-I expression in the bone microenvironment 
(5), has been shown to be an early crucial determinant of 
bone impairment in CCLD. 
Bisphosphonates are potent inhibitors of bone resorp-
tion, usually indicated for patients with clinically significant 
osteoporosis, namely postmenopausal women with a bone 
mineral density T-score below -2.5 or with pathological bone 
fracture. In addition, according to the American College of 
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Rheumatology, it is also indicated for the primary prevention 
of glucocorticoid-induced osteoporosis (6). In this context, 
attempts to extend the list of diseases, which would benefit 
from primary prevention with bisphosphonate treatment must 
be counterbalanced by considering an array of peculiarities 
and potentially negative issues: a) the mechanism behind 
bone loss, i.e., decreased bone formation or increased bone 
resorption, b) concerns exist about how long bone remodeling 
could artificially be inhibited by anti-resorptive drugs without 
serious impairment of bone repairing capacity (7), and c) the 
effectiveness of pharmacologic therapy in the prevention of 
osteoporosis in young individuals (8). 
Bone mineral density assessment represents a landmark 
in the clinical investigation and diagnosis of osteoporosis. 
However, this surrogate end point represents a partial evalua-
tion of bone strength and an increase in bone mineral density 
does not necessarily mean a reduction of fracture risk. Ani-
mal models, especially of rodents, have made an extensive 
contribution to the advancement of the understanding of the 
mechanistic role of several factors in the etiopathogenesis 
of osteoporosis (9,10). Thus, translational research in mice 
and rats is a fundamental tool for the development of new 
drugs and the design of new treatment schemes. However, 
an important limitation of the study of osteoporosis in small 
animal models is the lack of fracture due to bone insufficiency 
(11). Biomechanical tests have been a reasonable option to 
circumvent this limitation and are used extensively for the 
experimental analysis of bone strength (12,13). 
In this scenario, the major objective of the present study 
was to evaluate the beneficial effect of disodium pamidronate 
(pamidronate) as primary prevention therapy for hepatic 
osteodystrophy in CCLD. Rats submitted to bile duct ligation 
(BDL) surgery received pamidronate before and 1 month after 
surgery (primary prevention) or only 1 month after surgery. 
The results obtained with these two groups were compared 
to those obtained with the sham-operated group and another 
group submitted only to BDL. Biochemical evaluation of 
mineral metabolism and liver function was performed, the 
expression of IGF-I and of growth hormone receptor (GHR) 
in the growth plate was evaluated in all animals and bone 
histomorphometry of the tibia and biomechanical assays of 
the femur were also analyzed.
Material and Methods
All experimental designs and procedures were approved 
by the Animal Research Ethics Committee of the Faculdade 
de Medicina de Ribeirão Preto, USP. Forty-five 2-month-old 
male Wistar rats, housed individually at 25°C on a 12:12-h 
light-dark cycle, were used in this study. They were strictly 
pair-fed a laboratory diet provided by Nuvital (Nuvilab CR1; 
Brazil) containing 22% protein, 53% carbohydrate, and 
4.5% lipid. Animals had free access to water. Rats sub-
jected to BDL surgery were used as reference. The study 
was comprised of 4 groups of male Wistar rats weighing 
150-175 g: a) sham-operated rats (Sham, N = 12); b) rats 
subjected to bile duct ligation surgery (Bi, N = 15); c) rats 
subjected to bile duct ligation surgery plus pamidronate 
as primary prevention therapy administered before and 1 
month after the procedure (Pr, N = 9); d) rats subjected to 
bile duct ligation surgery plus pamidronate as conventional 
therapy, administered 1 month after the procedure (Tr, N = 
9). The protocol was repeated 3 times, each comprised of 4 
rats in the Sham group and 6 rats in the groups submitted 
to BDL. Three rats in the Bi group and 9 rats in the Pr and 
Tr groups died during the period of observation. All groups 
were followed for 2 months after surgery; pamidronate 
was injected intraperitoneally at the dose of 1.0 mg/kg 
body weight. Vehicle (0.9% sodium chloride) was injected 
in Sham and Bi groups. At the end of the second month, 
all rats submitted do BDL showed clinical manifestations 
of cholestatic disease. 
Bile duct ligation technique
Anesthesia was induced by intraperitoneal injection of 
2.5% tribromoethanol (Aldrich, USA; 250 mg/kg body mass). 
A median laparotomy was performed and the common bile 
duct was exposed and doubly ligated as described previ-
ously. In Sham rats, the procedure consisted of exposure 
of the liver hilum, which was gently mobilized with a sterile 
cotton applicator. After surgery, the BDL groups were in-
jected intramuscularly once a week with vitamin K (8 mg/kg 
body weight). Sham rats were injected with an equivalent 
volume of saline infusion (0.9% sodium chloride). 
Biochemical analysis
Blood collections were performed at baseline (2 mL 
from the tail) and at sacrifice when 7 mL blood was drawn 
from the left ventricle. The samples were maintained on ice 
and then centrifuged at 4°C. Serum aliquots were immedi-
ately used for the determination of albumin, total calcium, 
inorganic phosphorus, bilirubin, alanine aminotransferase 
(ALT), and aspartate aminotransferase (AST). 
Biomechanical evaluation
Biomechanical tests. Frozen femora were thawed at 
room temperature for 2 h before testing. Mechanical tests 
were performed on intact right femora using a destructive 
three-point bending procedure. The femur was placed 
supine on two round bars at a distance of 20 mm in a 
mechanical testing machine (10,000 N, EMIC, Brazil) and 
deflected by a notched bar on the opposite side of the bone. 
The descending speed of the notched bar was 1 mm/min. 
Maximal force and stiffness were determined from force/
deflection plots.
Histological assessment
Quantitative static and dynamic bone histomorphometry 
was performed as described previously (5). To measure 
bone formation rates, tetracycline label (20 mg/kg body 
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weight) was injected intraperitoneally 7 and 2 days before 
sacrifice. The right tibia was removed and dehydrated in 
ethanol, infiltrated and embedded without demineralization 
in methyl methacrylate. Undecalcified sections were cut at 
a thickness of 5 µm and mounted unstained for dynamic 
measurements. Consecutive sections were stained with 
toluidine blue to quantify bone cells. The histomorpho-
metric indexes are reported according to the standardized 
nomenclature recommended by the American Society of 
Bone and Mineral Research (14).
Bone specimens for immunohistochemical analysis 
were processed as previously described (5). Briefly, bone 
samples were sectioned at the growth plate at a thickness 
of 4 µM from paraffin blocks containing representative 
samples and mounted on poly-L-lysine-coated slides. 
Nonspecific protein binding was blocked with normal 
serum (Novostain Universal Super ABC Kit; Novocastra 
Laboratories, UK) for 30 min. The sections were then 
incubated with primary monoclonal antibodies specific for 
IGF-I (1:200; American Diagnostic, USA) and GHR (1:100, 
American Diagnostic). Next, the slides were incubated with 
the avidin-biotin-peroxidase complex (Novostain Universal 
Super ABC Kit), counterstained with Harris hematoxylin, 
dehydrated, and mounted with Permount (Biomeda, USA). 
As negative controls, all specimens were incubated with a 
control antibody under identical conditions. The prepara-
tions for each marker were evaluated at random in at least 
10 representative high-power fields (40X magnification), 
and graded according to their intensities and percentage 
of positive cells. Cells were designated as positive when 
they displayed a distinct brown cytoplasm staining. Semi-
quantitative expression was scored as follows: 0, no stained 
cells; +, fewer than 10% positive cells; ++, 10-50% positive 
cells; +++, >50% positive cells. 
Statistical analysis
Data are reported as means ± SEM. Statistical signifi-
cance was determined using ANOVA followed by the Tukey 
test for multiple comparisons, and the Pearson correlation 
coefficient was employed for the analysis of correlation 
between parametric variables using the GraphPad Prism 
software (GraphPad Prism, USA)
Results
There was no significant difference in body weight be-
tween groups either at baseline (Sham = 164.3 ± 3.5; Bi = 
164.9 ± 2.7; Pr = 165.3 ± 2.3; Tr = 166.3 ± 1.9 g) or at the 
end of the experiment (Sham = 483.6 ± 55.3; Bi = 458.7 
± 60.4; Pr = 438.8 ± 62.4; Tr = 448.8 ± 68.4 g). All groups 
exhibited significant weight gain during the 2 months of 
observation (P < 0.001). 
Sham-operated animals exhibited no variation in se-
rum albumin levels during the experiment, while the other 
groups showed decreased levels of serum albumin at the 
end of the study. At sacrifice, the three groups submitted 
to BDL showed lower serum levels of albumin than the 
Sham group, P < 0.01 (Table 1), whereas hepatic enzymes 
[gamma-glutamyl transpeptidase (γGT), alkaline phos-
phatase, ALT, and AST] and bilirubin increased significantly 
in these 3 groups compared to the Sham group (Table 1). 
No significant differences in the levels of hepatic enzymes 
were observed between the groups submitted to surgery for 
ligation of the bile duct, i.e., hepatic enzymes were similar 
Table 1. Biochemical evaluation of rats under basal conditions and at 60 days after sham surgery (Sham), bile duct ligation (BDL) sur-
gery (Bi), BDL surgery plus pamidronate prevention therapy (Pr, basal and 30 days after surgery), and BDL surgery plus pamidronate 
therapy (Tr) 30 days after surgery.
Sham (N = 12) Bi (N = 15) Pr (N = 9) Tr (N = 9)
Basal 60 days Basal 60 days Basal 60 days Basal 60 days
Albumin (g/L) 38 ± 1 37 ± 1 37 ± 1 28 ± 1* 38 ± 1 30 ± 4* 39 ± 1 29 ± 4*
Corrected calcium
(mM)
2.40 ± 0.10 2.38 ± 0.13 2.38 ± 0.13 2.48 ± 0.18 2.35 ± 0.08 2.43 ± 0.13 2.33 ± 0.10 2.38 ± 0.22
Phosphorus (mM) 1.81 ± 0.16 1.84 ± 0.16 1.87 ± 0.19 1.97 ± 0.26 1.74 ± 0.19 1.91 ± 0.32 1.84 ± 0.13 1.91 ± 0.23
γGT ((U/L) 7.8 ± 0.3 7.9 ± 0.3 7.6 ± 0.5# 46.3 ± 4.6** 7.4 ± 0.6# 48.9 ± 5.2** 7.7 ± 0.4# 47.8 ± 4.2**
Alkaline 
phosphatase (U/L)
118.0 ± 4.5 115.0 ± 5.5 115.0 ± 3.6## 1654.0 ± 114.9*** 116.0 ± 4.6## 1754.0 ± 122.6*** 117.0 ± 0.4## 1689.0 ± 119.3***
ALT (U/L) 28.0 ± 3.5 26.0 ± 4.5 26.5 ± 3.6# 174.7 ± 6.6** 27.7 ± 4.6# 193.7 ± 8.6** 25.4 ± 2.4# 178.4 ± 7.6**
AST (U/L) 32.5 ± 4.5 30.5 ± 5.5 31.5 ± 4.6# 144.6 ± 7.6** 33.7 ± 3.4# 156.6 ± 6.6** 33.6 ± 3.8# 154.7 ± 8.6**
Total bilirubin (µM) 10.3 ± 0.17 12.0 ± 0.17 8.6 ± 0.20# 152.2 ± 17.1** 10.3 ± 0.34# 156.6 ± 30.8** 10.3 ± 0.17# 153.9 ± 29.7**
Direct bilirubin (µM) 6.8 ± 0.17 8.6 ± 0.17 6.9 ± 0.34# 133.4 ± 15.4** 6.8 ± 3.4# 147.1 ± 15.4** 6.8 ± 0.17# 143.6 ± 15.4**
Indirect bilirubin (µM) 3.5 ± 0.17 3.4 ± 0.17 1.7 ± 0.17# 18.8 ± 10.3** 3.5 ± 0.17# 9.5 ± 0.5** 3.5 ± 0.17# 10.3 ± 5.1**
Data are reported as means ± SEM. γGT = gamma-glutamyl transpeptidase; ALT = alanine aminotransferase; AST = aspartate aminotrans-
ferase. *P < 0.01, 60 days Bi, Pr, Tr compared to 60 days Sham; **P < 0.001, 60 days Bi, Pr, Tr compared to 60 days Sham; #P < 0.001, 
basal Bi, Pr, Tr compared to 60 days Bi, Pr, Tr, respectively; ***P < 0.0001, 60 days Bi, Pr, Tr compared to 60 days Sham; ##P < 0.0001, 
basal Bi, Pr, Tr compared to 60 days Bi, Pr, Tr, respectively (ANOVA followed by the Tukey test for multiple comparisons).
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in animals treated with vehicle or pamidronate. There were 
no significant differences in serum levels of corrected total 
calcium and phosphorus between groups (Table 1).
CCLD affected negatively bone microarchitecture; 2 
months after BDL, bone material volume over tissue volume 
(BV/TV) and trabecular thickness were decreased, whereas 
trabecular separation was enhanced in the Bi group. On 
the other hand, pamidronate reversed all of these altera-
tions and both groups subjected to preventive (Pr) and 
secondary (Tr) pamidronate treatment showed significantly 
greater BV/TV and trabecular thickness and significantly 
lower trabecular separation than the Sham and Bi groups 
(Table 2). Bone formation parameters were not significantly 
affected by cholestasis. However, pamidronate induced a 
reduction in osteoblast number (e.g., osteoblast surface/
bone surface: Sham = 11.2 ± 4.7; Bi = 12.4 ± 8.4; Pr = 5.6 
± 1.9; Tr = 6.9 ± 3.0%; P < 0.05, Bi vs Pr) and in osteoblast 
activity (e.g., bone formation rate/bone surface: Sham = 
46.3 ± 36.8; Bi = 36.5 ± 15.4; Pr = 9.5 ± 6.3; Tr = 11.1 ± 3.6 
µm2·(µm3)-1·day-1; P < 0.05, Sham vs Pr, Sham vs Tr, Bi vs 
Pr). The bone resorption in Bi was similar to that observed 
in Sham. However, pamidronate induced high suppression 
of the number of osteoblasts and of osteoblastic activity in 
the tibiae (Table 2). 
There were no significant differences in IGF-I or GHR 
expression in the tibial growth plate cartilage of the four 
groups (Table 3). 
Table 4 shows that the maximum force necessary to 
fracture bone was not significantly higher in the Sham 
group compared to both the group with obstructed bile 
duct without treatment and to the group with obstructed bile 
duct receiving pamidronate as treatment. In the cholestasis 
group and in the cholestasis group receiving pamidronate 
treatment the lowest force necessary to induce fracture 
Table 2. Histomorphometric evaluation of the proximal tibial metaphysis at 60 days after sham sur-
gery (Sham), bile duct ligation (BDL) surgery (Bi), BDL surgery plus pamidronate prevention therapy 
(Pr, basal and 30 days after surgery), and BDL surgery plus pamidronate therapy (Tr) 30 days after 
surgery. 
Sham (N = 12) Bi (N = 15) Pr (N = 9) Tr (N = 9)
Structure
BV/TV (%) 18.1 ± 3.2 10.6 ± 2.2** 39.4 ± 12.0* 41.2 ± 12.7*
Tb.Th (µm) 71.7 ± 8.8 66.6 ± 11.8 81.8 ± 6.5 71.0 ± 12.1
Tb.N (/mm) 2.6 ± 0.6 1.6 ± 0.2** 4.9 ± 1.4* 5.8 ± 1.7*
Tb.Sp (µm) 337.0 ± 88.2*** 566.8 ± 75.1 135.6 ± 53.0# 112.5 ± 52.0#
Formation
OV/TV (%) 0.6 ± 0.4## 0.4 ± 0.3## 0.9 ± 0.6 1.2 ± 0.6
OV/BV (%) 3.8 ± 1.8 4.2 ± 3.0 2.0 ± 1.1 3.2 ± 1.5
OS/BS (%) 34.8 ± 16.5 35.2 ± 24.2 19.0 ± 9.9 27.4 ± 9.4
Ob.S/BS (%) 11.2 ± 4.7 12.4 ± 8.4 5.6 ± 1.9### 6.9 ± 3.0
O.Th (µm) 7.7 ± 1.7 7.1 ± 0.9 8.3 ± 1.6 8.6 ± 2.0
N.Ob/B.Pm (/mm) 3.9 ± 1.6 4.1 ± 2.1 2.3 ± 0.9 3.1 ± 1.3
MAR (µm/day) 0.57 ± 0.3 0.71 ± 0.09 0.42 ± 0.12+ 0.49 ± 0.09+
BFR/BS (µm2·(µm3)-1·day-1) 46.3 ± 36.8 36.5 ± 15.4+++ 9.5 ± 6.3++ 11.1 ± 3.6++
Aj.AR (µm/day) 0.18 ± 0.1 0.29 ± 0.1 0.13 ± 0.05¶ 0.14 ± 0.07¶
Mlt (day) 49.8 ± 29.7 32.2 ± 22.7 71.2 ± 31.9¶ 71.8 ± 30.0¶
Resorption
N.Oc/B.Pm (/mm) 0.9 ± 0.4 1.1 ± 0.3 0.3 ± 0.2 0.4 ± 0.3
ES/BS (%) 5.4 ± 2.7 6.6 ± 2.2 2.0 ± 1.5 2.3 ± 1.7
Oc.S/BS (%) 4.1 ± 2.0 5.1 ± 1.9 1.3 ± 0.8 1.6 ± 1.4
Data are reported as means ± SEM. BV = bone volume; TV = tissue volume; Tb.th = trabecular thick-
ness; Tb.N = trabecular number; Tb.sp = trabecular separation; OV = osteoid volume; OS = osteoid 
surface; BS = bone surface; Ob.S = osteoblast surface; O.Th = osteoid thickness; N.Ob = osteoblast 
number; B.Pm = bone perimeter; MAR = mineral apposition rate; BFR = bone formation rate; Aj.AR = 
adjusted apposition rate; Mlt = mineralization lag time; N.Oc = osteoclast number; ES = eroded sur-
face; Oc.S = osteoclast surface. *P < 0.001, Pr and Tr compared to Sham; **P < 0.001, Bi compared 
to Pr and TR; ***P < 0.001, Sham compared to Bi, Pr and TR; #P < 0.001, Pr and TR compared to 
Bi; ##P < 0.05, Sham and Bi compared to Tr; ###P < 0.05, Pr compared to Bi; +P < 0.05, Pr and Tr 
compared to Bi; ++P < 0.05, Pr and Tr compared to Sham; +++P < 0.05, Bi compared to Pr; ¶P < 0.05, 
Pr and Tr compared to Bi (ANOVA followed by the Tukey test for multiple comparisons).
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was decreased to about the same level, 18.9 
and 20.7%, respectively, compared to control. In 
parallel, in the group that received pamidronate 
as a preventive scheme the force on the momen-
tum of fracture was even more reduced (29.0%, 
P < 0.05). 
Discussion
The present study showed that pamidronate 
used for primary prevention therapy, administered 
immediately before and 1 month after surgery-
induced cholestasis, enhances bone mass. How-
ever, primary prevention therapy had no additional 
advantage in comparison to conventional treatment (i.e., 
therapy initiation after established bone disease, 1 month 
after cholestasis). The improvement in bone microstructure 
of animals treated by primary prevention therapy was similar 
to the benefit observed in the group in which pamidronate 
treatment was started only after established bone disor-
der. Additionally, the force required to fracture bone from 
animals treated with primary prevention was lower than 
that required to fracture bone from animals treated with 
secondary prevention therapy.
Bisphosphonates decrease fracture risk in large part 
by reducing the rate of bone remodeling and associated 
microarchitectural bone deterioration as well as by increas-
ing bone mass. Bone remodeling is the mechanism by 
which bone repairs microdamage and delivers calcium into 
the circulation (15,16). Bone formation rates estimated by 
tetracycline labeling are reduced in patients on bisphospho-
nates. Most patients on bisphosphonates show reductions 
in remodeling to the range seen in healthy premenopausal 
women (17). The primary end-point required for Food and 
Drug Administration (FDA) approval of therapies for the 
treatment of postmenopausal osteoporosis is significant 
reduction in incident morphometric vertebral fractures over 
3 years compared with placebo (18). The extensive experi-
ence accumulated in osteoporosis treatment involves post-
menopausal women, showing severe densitometric bone 
loss or established osteoporosis, which means a previous 
history of fracture (19-21).
Currently, glucocorticoid-induced osteoporosis (GIO) 
is the sole clinical condition for which the use of bispho-
sphonates is advocated for primary prevention (6). This 
approach is based on the pathophysiology of GIO, namely 
the occurrence of two distinct phases of bone loss, the 
first involving a fast bone remodeling rate and the second 
involving a slow process of bone loss. In GIO, the early 
use of a potent antiresorptive drug prevents the increment 
of bone resorption activity and bone loss. Although some 
studies have suggested that osteoporosis in CCLD is due 
to a combination of decreased bone formation and acceler-
ated bone resorption (22,23), most studies describe a more 
conspicuous impairment of bone formation (24,25). Studies 
on hepatic osteodystrophy in humans have indicated that 
the most striking change in the profile of biochemical mark-
ers of bone remodeling is the reduction of osteocalcin, i.e., 
reduction in the activity of bone formation (26,27). These 
data are supported by results obtained in histomorphometric 
evaluation in experimental models of CCLD (5) as well as 
in humans (28,29).
In a previous study on 2-month-old Wistar rats, we 
Table 3. Insulin-like growth factor-I (IGF-I) and growth hormone receptor (GHR) expression in the 
proximal tibial metaphysis at 60 days after sham surgery (Sham), bile duct ligation (BDL) surgery (Bi), 
BDL surgery plus pamidronate prevention therapy (Pr, basal and 30 days after surgery), and BDL 
surgery plus pamidronate therapy (Tr) 30 days after surgery.
Sham (N = 12) Bi (N = 15) Pr (N = 9) Tr (N = 9)
IGF-I GHR IGF-I GHR IGF-I GHR IGF-I GHR
0 4 (33.3) 8 (66.6) 7 (46.7) 9 (60.0) 3 (33.3) 3 (33.3) 6 (66.6) 4 (44.4)
+ 7 (58.3) 4 (33.3) 4 (26.7) 3 (20.0) 1 (11.1) 6 (66.6) 3 (33.3) 5 (55.6)
++ 1 (8.3) 0 (0) 4 (26.7) 3 (20.0) 5 (55.6) 0 (0) 0 (0) 0 (0)
+++ 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Data are reported as number of animals with percent in parentheses. (0) = no stained cells; (+) = fewer 
than 10% positive cells; (++) = 10-50% positive cells; (+++) = >50% positive cells.
Table 4. Biomechanical evaluation of the femur at 60 days after sham surgery 
(Sham), bile duct ligation (BDL) surgery (Bi), BDL surgery plus pamidronate 
prevention therapy (Pr, basal and 30 days after surgery), and BDL surgery 
plus pamidronate therapy (Tr) 30 days after surgery.
Sham (N = 12) Bi (N = 15) Pr (N = 9) Tr (N = 9)
Length (mm) 39.4 ± 3.1 37.5 ± 3.3 39.0 ± 1.4 37.5 ± 2.6
Ultimate load (N) 116.6 ± 23.0 94.6 ± 33.8 82.9 ± 22.8* 92.5 ± 29.5
Stiffness (N/mm) 129.0 ± 77.8 90.3 ± 52.4 67.2 ± 1.5 72.6 ± 7.6
Data are reported as means ± SEM. *P < 0.05, Pr compared to Sham 
(ANOVA followed by the Tukey test for multiple comparisons).
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have shown that four weeks after BDL surgery there are 
clear signs of osteoporosis determined by bone histomor-
phometry, expressed as decreased BV/TV and osteoblast 
number (5). In the present study, the previous evidence 
was replicated with a more severe pattern after 2 months 
of cholestasis. Additionally, we observed the efficiency of 
pamidronate in reversing the process of bone loss. Animals 
treated with pamidronate 1 month after BDL exhibited in-
creased bone volume (BV/TV), as well as high trabecular 
thickness and trabecular number. On the other hand, his-
tomorphometric data showed that there was no additional 
benefit when pamidronate was used for primary prevention, 
i.e., the improvement of bone structure was of the same 
magnitude as that observed when treatment was started 
only after established bone disease. Furthermore, the bone 
capacity to withstand mechanical stress was decreased 
in femur specimens from animals subjected to primary 
prevention treatment compared to those obtained from 
animals treated with the secondary regimen. Similar to our 
study, there are data showing that distinct bisphosphonates 
are able to prevent trabecular osteopenia in ovariectomy, 
a classical experimental model of osteoporosis (13,30). 
These studies observed improvement in the ultimate force 
for bone fracture only in lumbar spine bone and, similar to 
our results, no effect was verified in long bones of animals 
subjected to bisphosphonate treatment (13,30,31). Kippo 
et al. (31) suggested that in the rat the amount of cortical 
bone and external bone dimensions would contribute more 
to the structural strength of the femur than the amount and 
microarchitecture of trabecular bone. In addition to those 
studies, the present investigation showed that pamidronate 
used as preventive treatment may impair bone strength in 
rats submitted to surgically induced cholestasis. Femur 
from cholestatic rats submitted to preventive pamidronate 
treatment showed a decreased ultimate load for fracture 
and a trend to reduced stiffness. These results agree with 
previous data showing an inverse correlation between 
intraosseous concentration of pamidronate and ultimate 
load at failure and stiffness (32).
Other histomorphometric parameters indicate impair-
ment of bone remodeling activity in the tibia from BDL rats 
subjected to preventive pamidronate therapy. Alteration 
in skeletal mineralization and decreased bone repairing 
capacity were demonstrated by an increased time required 
for mineralization and a concomitant decrement in the num-
ber of osteoclasts and on surface resorption area in BDL 
animals treated with pamidronate. Although the number 
of osteoblasts was not decreased in pamidronate-treated 
animals, these animals exhibited a lower bone formation 
rate. Taken together, these results indicate impaired turn-
over and accumulation of microcracks due to suppressed 
osteoclast-mediated bone resorption. 
No difference in IGF-I or GHR expression in growth 
cartilage was detected between animals treated with both 
pamidronate regimens and vehicle. Most likely, this occur-
rence reflects the animals’ age since no difference was also 
observed between sham-operated animals and the other 
three groups. In a previous study, we detected a significant 
decrease in IGF-I and GHR expression in 3-month-old 
Wistar rats submitted to BDL surgery. It is well known that 
the age-related decline in the expression of IGF-I is part of 
the maturation process (33). Thus, the different results are 
probably due to the distinct ages of the experimental rats. 
Liver-derived and autocrine/paracrine IGF-I are both crucial 
components for bone mass development and maintenance 
(34-36). In the present study, the serum levels of IGF-I were 
not measured, but liver-derived IGF-I is characteristically 
decreased in cholestatic diseases. 
Therefore, the present study shows that pamidronate 
is highly effective in inducing an apparent improvement in 
bone microstructure in an experimental model of CCLD. 
The data also show that early pharmacological treatment 
used as primary prevention does not represent a better ap-
proach. Histomorphometric evaluation demonstrated that 
cholestatic animals submitted to a primary or secondary 
treatment regimen exhibit the same bone volume. However, 
bone strength tested by biomechanical assays showed a 
better capacity to resist mechanical stress in rats treated 
with a secondary regimen. 
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